Empery Asset Management LP purchased a new position in Sunshine Biopharma, Inc. (NASDAQ:SBFM – Get Rating) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 450,450 shares of the company's stock, valued at approximately $1,104,000. Sunshine Biopharma makes up about 5.2% of Empery Asset Management LP's investment portfolio, making the stock its 5th largest holding. Empery Asset Management LP owned 2.73% of Sunshine Biopharma as of its most recent SEC filing.
Sunshine Biopharma Price Performance
NASDAQ SBFM opened at $1.06 on Tuesday. The stock's 50 day moving average is $1.15 and its 200 day moving average is $1.99. Sunshine Biopharma, Inc. has a 12 month low of $1.01 and a 12 month high of $29.80.
Get
Sunshine Biopharma alerts:
About Sunshine Biopharma
(Get Rating)
Sunshine Biopharma, Inc, a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound.
Further Reading
- Get a free copy of the StockNews.com research report on Sunshine Biopharma (SBFM)
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
Want to see what other hedge funds are holding SBFM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sunshine Biopharma, Inc. (NASDAQ:SBFM – Get Rating).
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
